Quick Answer
BioXcel Therapeutics, Inc. reported Operating Income Loss of -$50.46 million for the year ending 2025.
- BioXcel Therapeutics, Inc. showed an increase of +25.0% in Operating Income Loss from 2024 to 2025.
- This data is from BioXcel Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), BioXcel Therapeutics, Inc.'s Operating Income Loss has declined by 1,012.2%.
- Historical annual values: Fiscal year 2025: -$50.46 million | Fiscal year 2024: -$67.25 million | Fiscal year 2023: -$171.78 million | Fiscal year 2022: -$159.65 million | Fiscal year 2021: -$106.94 million | Fiscal year 2020: -$82.30 million | Fiscal year 2019: -$33.60 million | Fiscal year 2018: -$19.96 million | Fiscal year 2017: -$4.54 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: